It was learned that the domestic microfluidic chip sensor and system provider Chuanghuai Medical completed a new round of financing. This round of financing was led by the Miracle Light Fund of Huada Group and Zhejiang Xianghui Capital jointly invested. At present, this is the single largest financing for the domestic microfluidic industry. The last round of investment came from Xianyu Capital. Zhuang Bin, CEO of Chuanghuai Medical, said that this round of financing will be mainly used for product registration and product development. Chuanghuai CEO Zhuang Bin revealed that in the next six months, Chuanghuai Medical also plans to build the world's largest biochip production research center. To this end, on October 10, 2018, China National Development and Reform Commission China Investment Association and Chuanghuai Medical signed a long-term strategic investment and cooperation agreement! Encourage and support the promotion of Chuanghuai's advanced primary medical chip technology to the whole country and integrate into the health and fitness strategy. Zhao Yuwen, vice president of Miracle Light of Huada Group, said: "The reason why we choose to create a brand, first, in the definition of future standards in the microfluidic industry, technology accumulation, market ability, and innovation is very obvious. In cooperation with Huada, the prenatal screening business of Huada Gene under the Huada Group can be seamlessly connected with the pregnant family of Chuanghuai, and we can look forward to the in-depth cooperation. Third, under the Huada Group Huada has developed advanced diagnostic instruments and has a prospect of cooperation with Chuanghuai's microfluidic diagnostic chip." Dr. Zhang Wei, the investment director of Xianghui Capital, believes that the investment in Chuanghuai Medical is based on the high recognition of the company's globally innovative medical testing technology and products, and full confidence in the company's future growth space. In the future, deep cooperation will be carried out at a broader level. The grassroots layer is the market for microfluidics Microfluidic chips are called "lab-on-a-chips", which can compress the inspections that were previously completed in large laboratories onto a small chip. Microfluidic control has the advantages of high automation and integration. The construction of a miniature reaction and analysis unit on the surface of a solid chip enables rapid and accurate detection of inorganic ions, organic substances, nucleic acids, proteins and other biochemical components. The microfluidic chip can greatly shorten the sample processing time, and achieve the maximum utilization efficiency of reagent consumables by precisely controlling the liquid flow, integrating the functions of the entire laboratory, including sampling, dilution, reagent addition, reaction, separation, detection, etc. On the chip, and can be used multiple times. Also known as "on-chip lab." Microfluidic can also be widely used in many fields such as biomedical research, drug synthesis screening, environmental monitoring and protection, health quarantine, and forensic identification outside of IVD. Throughout the micro-fluidic track, there are not many companies running. Because the microfluidics industry has high technical barriers, microfluidic chip technology needs to integrate three technologies: semiconductor technology, biosensor knowledge, and precision injection molding technology. It can be said that the manufacture of microfluidic chips is like the language of the people who build the Tower of Babel. Zhuang Bin has just the background of these three disciplines. After returning to China, Zhuang Bin worked for Mindray and the Chinese Academy of Sciences in charge of related technology research and development, and participated in the development of Mindray's first five-class blood analyzer in China. There are also many researchers from multinational corporations, universities and research institutes throughout the core team. In the field of microfluidic chips, it is necessary to build barriers with core technologies, but at the same time it is equally important to choose a commercial path to achieve product landing. It is reported that the market size of microfluidic chips in 2015 is about 2.8 billion US dollars. By 2018, the market size is 5.8 billion US dollars, with a compound annual growth rate of over 27%. In the domestic market environment, the main market for microfluidics in the future should be in the primary medical market. The grassroots has a huge demand for inspection. On the other hand, the signal of continuous release of a series of policies such as national grading medical treatment and family doctors is the focus of this round of medical reform at the grassroots level. Zhuang Bin, CEO of Chuanghuai Medical, said to the arterial network: "There are currently 2.58 billion primary-level clinics in the grassroots in China without any tests. This grassroots level mainly refers to social health and village health clinics. Seeing a doctor is to see a doctor, and the eye is right. You can take the medicine." Specifically, it covers 911,000 community health centers, township health centers, village clinics, and clinics scattered across China's land. (The figures come from the Statistical Yearbook of the Ministry of Health) 68% of which are untested. Zhuang Bin vividly said: "The name has a '院', we think that he has certain inspection capabilities. And what, room Almost none of the inspection capabilities." How to replenish the "barren" primary health care system in the direction of national assistance, medical, medicine, and inspection are the three main directions. In addition, more than half of the doctors in China do not have a bachelor's degree. Therefore, in the three links of medicine, medicine and inspection, the link to increase the structural contradiction of medical structure is indispensable. Because of the grassroots level, on the one hand, primary medical institutions are in urgent need of routine testing, especially blood routine testing, followed by urine routine and other inflammatory tests, followed by biochemistry outside the three routines, but on the other hand, traditional blood analyzers, Traditional large-scale biochemical instruments, etc., are difficult to sink to primary medical institutions, so the market size of small conventional POCTs in the future will be very large. For blood analyzers that require routine blood testing, there are several meters of pipeline inside the instrument that must be cleaned and maintained for each test. Tens of leaky valves and pump components are used, and several reagent barrels are required outside the instrument. Waste liquid drums also require professionals to regularly calibrate and clean the instrument. The same is true for large-scale detectors required for biochemical testing. Not only do they need to be equipped with centrifuges, water purifiers, etc., but also professionals need to regularly calibrate the instrument and clean the pipeline. Primary medical institutions cannot handle medical wastewater. At the same time, due to the characteristics of “network dot dispersion and low utilization rate†at the grassroots level, it is difficult for manufacturers to go to the door for maintenance and repairs. These are the pain points of traditional blood analyzers and biochemical analyzers. Microfluidic technology can solve these problems well. When choosing the product to land, Chuanghuai Medical first launched a microfluidic blood analyzer. "At the beginning, everyone will say that you are doing blood routine, which sounds lower than biochemical and immunodiagnosis. In fact, the threshold of microfluidic blood conventional chips is extremely high, Beckman Coulter, NASA, Philips, etc. The international giants have not developed successfully for more than a decade. We Chinese have come out, and I can't do biochemistry, immunity, and genes. I think blood routines are the first of the three routines, and it is more in line with market demand. Other products are of little value to the grassroots at this stage," said Zhuang Bin. Note: The primary medical institutions in the picture do not include township hospitals. In addition to the unique path in the medical scene, do not follow the strategy. In the family scene, Chuanghuai Medical also chose to enter the market with a mobile phone sperm analyzer (Intelligent Pregnancy Instrument). Zhuang Bin said: "I think the family always has its own atmosphere. It is impossible to turn it into a medical scene with many instruments. But the family has a big, and the most suitable medical requirement for home preparation is pregnancy. For pregnancy preparation Men are actually more important. Women discharge more than 400 follicles in their lifetime. The quality is actually relatively stable, while men produce 100 million sperm per day. The composition of each sperm is different." Chuanghuai Medical's mobile phone sperm analyzer (intelligent preparation instrument) is done by microscopic examination. The consumer collects the sample and puts it into the patented imaging cup (microfluidic slide), and directly puts it on the preparation instrument with the mobile phone camera. He can see the shape of the sperm directly. At the same time, after the user uploads the image to the cloud server, the cloud server can analyze the sperm quality and give a reference for pregnancy. At present, this preparation instrument called the male bemaner also won the 2018 German iF and red dot (REDDOT) world's top design double material award. Zhuang Bin introduced that the imaging cup uses one of the microfluidic technologies. Zhuang Bin calls it a series of microfluidic technology, which immediately converts the cells into microscopic image signals. Users use any mobile phone, not Any manual adjustment of the focus is required (conventional microscopes require complex focusing) to see clear high-power microscopy images directly on the phone. Create a micro-fluidic open platform to redefine the market Choosing from the blood routine, Zhuang Bin said: "The first is to start from the logic of market demand, and the second is to hope that mass production can be achieved in the early stage and then lead the industry standard. To create a micro-fluidic open platform with the ability to define the market. "" Choosing such industrialization logic, Zhuang Bin is a micro-flow control and a technical barrier with high technical barriers but low commercialization. And the medical device giant also has a certain market share. How to get out of the shadow of the giants, to achieve import substitution, and even to redefine the market's ability to become a bottleneck in microfluidic product innovation. In this step, Chuanghuai Medical also used the product to make a layout for the game. Zhuang Bin explained to the arterial network: "In the entire biochip industry, I hope to develop four series of sensors, "light, electricity, color, and map", which convert cells, blood or other biological signals into optical signals and electrical signals. Color signal and image recognition signal. The whole inspection medicine chip is unified into these four series to create an open system. Chuanghuai has developed the first generation of these four series of chips, the blood routine is the electric series chip One of the applications, the electric series can also do for example AIDS diagnosis, Chuanghuai will be launched soon; sperm analysis is one of the application of the series of chips, the figure series can also do such as urine sediment analysis, etc. One of the applications of the color series is biochemistry. One of the applications of the light series is immunity." Why choose such a layout, first of all, based on the existing difficulties of the industry. "In the entire medical device industry, it can be divided into three kinds of people. One type of people learns electronic engineering. Their expertise is to develop instruments. The other type is graduated from biology. They are biased toward reagent companies. But if you want to make a The analyzer requires not only instruments, reagents, but also fluid systems. The fluid system decides where to place these fluids on the instrument, and the implanted sensors collect the signals and go to the electronics engineer's instrument." Zhuang Bin also pointed out that the three parts come from three different professions, which leads to the system being very closed and it is difficult to develop new products. What Chuanghuai wants to do is through the interactive liquid system. Biochemical professionals and electronic engineers do not need to know what the other party is doing, they can connect. The bio-specialist only needs to develop related reagents on the chip. The electronics engineering professional company only needs to collect signals on the chip for algorithm and analysis. Finally, Zhuang Bin said: "In the end, we hope that the IVD industry pattern is that medical instrument electronics engineers are like mobile phones. The standard microfluidic chips we developed are like Android systems, and bio-engineers are equivalent to development. APP. The entire industry has become an open system." In the interview, Zhuang Bin mentioned a sentence called "Innovation is no teacher." Indeed, it is difficult for innovation to re-take a path or replicate a model, only to constantly explore the right path and verify its ability and judgment. Personal Care,Hair Conditioner,Body Wash Shower Gel,Moisturizing Shower Gel Wuxi Keni Daily Cosmetics Co.,Ltd , https://www.kenidailycosmetics.com